Liposomal delivery of hydrophobic RAMBAs provides good bioavailability and significant enhancement of retinoic acid signalling in neuroblastoma tumour cells.


Journal

Journal of drug targeting
ISSN: 1029-2330
Titre abrégé: J Drug Target
Pays: England
ID NLM: 9312476

Informations de publication

Date de publication:
07 2020
Historique:
pubmed: 7 1 2020
medline: 28 9 2021
entrez: 7 1 2020
Statut: ppublish

Résumé

Retinoid treatment is employed during residual disease treatment in neuroblastoma, where the aim is to induce neural differentiation or death in tumour cells. However, although therapeutically effective, retinoids have only modest benefits and suffer from poor pharmacokinetic properties.

Identifiants

pubmed: 31903789
doi: 10.1080/1061186X.2019.1710157
pmc: PMC7609071
doi:

Substances chimiques

Azoles 0
Liposomes 0
Tretinoin 5688UTC01R
CYP26A1 protein, human EC 1.14.14.1
CYP26B1 protein, human EC 1.14.14.1
Retinoic Acid 4-Hydroxylase EC 1.14.14.1
Proto-Oncogene Proteins c-akt EC 2.7.11.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

643-654

Subventions

Organisme : Worldwide Cancer Research
ID : 12-1272
Pays : United Kingdom
Organisme : Medical Research Council
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom

Références

Biomaterials. 2011 Feb;32(5):1370-6
pubmed: 21074847
Br J Cancer. 2002 Feb 12;86(4):605-11
pubmed: 11870544
Annu Rev Pathol. 2011;6:345-64
pubmed: 21073338
Arterioscler Thromb Vasc Biol. 2007 Jul;27(7):1542-8
pubmed: 17510468
N Engl J Med. 1999 Oct 14;341(16):1165-73
pubmed: 10519894
Cancer. 2004 Feb 1;100(3):574-80
pubmed: 14745875
Br J Cancer. 2007 Feb 12;96(3):424-31
pubmed: 17224928
Expert Opin Drug Deliv. 2015 Feb;12(2):223-38
pubmed: 25224685
J Control Release. 2014 Dec 10;195:72-85
pubmed: 25094032
Curr Med Chem. 2007;14(29):3070-8
pubmed: 18220743
J Natl Cancer Inst. 1982 Apr;68(4):589-96
pubmed: 7040765
Adv Pharmacol. 2015;74:373-412
pubmed: 26233912
Acta Biomater. 2017 Mar 15;51:351-362
pubmed: 28110069
Br J Cancer. 2007 Jun 4;96(11):1675-83
pubmed: 17486130
Pharmacol Ther. 1989;40(1):145-55
pubmed: 2645587
Cell Mol Life Sci. 2015 Apr;72(8):1559-76
pubmed: 25558812
Clin Cancer Res. 2013 Jan 15;19(2):469-79
pubmed: 23087409
Cancer Lett. 2003 Jul 18;197(1-2):185-92
pubmed: 12880980
Expert Opin Drug Metab Toxicol. 2016 Sep;12(9):1021-33
pubmed: 27267126
Br J Cancer. 2007 Apr 23;96(8):1204-15
pubmed: 17387344
J Nanobiotechnology. 2018 Nov 27;16(1):97
pubmed: 30482196
Biomaterials. 2015 Nov;68:89-99
pubmed: 26276694
Therapie. 2007 Mar-Apr;62(2):91-3
pubmed: 17582307
J Control Release. 2014 Jan 28;174:177-87
pubmed: 24269968
FASEB J. 2010 Jul;24(7):2301-13
pubmed: 20203088
Mini Rev Med Chem. 2002 Jun;2(3):261-9
pubmed: 12370067
Bioorg Med Chem. 2012 Jul 15;20(14):4201-7
pubmed: 22727372
J Med Chem. 2011 Oct 13;54(19):6803-11
pubmed: 21838328
AAPS J. 2011 Dec;13(4):585-97
pubmed: 21904966
J Biol Chem. 2002 Jul 12;277(28):25297-304
pubmed: 12000752
Drug Metab Dispos. 2017 Jul;45(7):846-854
pubmed: 28446509
Br J Cancer. 2005 Feb 28;92(4):696-704
pubmed: 15714209
Curr Top Med Chem. 2013;13(12):1402-28
pubmed: 23688132
Br J Cancer. 2006 Feb 27;94(4):513-23
pubmed: 16449997
Mol Cancer Ther. 2008 May;7(5):1275-84
pubmed: 18483315
Drug Discov Today. 2012 Sep;17(17-18):1044-52
pubmed: 22652342
J Clin Oncol. 2009 Mar 1;27(7):1007-13
pubmed: 19171716
Blood. 1992 Jan 15;79(2):299-303
pubmed: 1309668
Biochem Biophys Res Commun. 2012 Aug 3;424(3):421-6
pubmed: 22766505
Biochemistry. 1993 Jan 26;32(3):889-99
pubmed: 8422393
Nat Rev Cancer. 2003 Mar;3(3):203-16
pubmed: 12612655
Semin Cutan Med Surg. 2012 Mar;31(1):11-6
pubmed: 22361284
J Control Release. 2016 Dec 28;244(Pt A):108-121
pubmed: 27871992
Expert Opin Drug Metab Toxicol. 2009 Aug;5(8):875-86
pubmed: 19519282
Biomaterials. 2014 Sep;35(29):8406-15
pubmed: 24985735
Oncogene. 1992 Apr;7(4):711-7
pubmed: 1565467
Biochem Pharmacol. 2010 Sep 15;80(6):903-12
pubmed: 20513361
Int J Cancer. 2017 Jul 15;141(2):405-413
pubmed: 28340497
Nature. 1985 Jan 31-Feb 6;313(6001):404-6
pubmed: 3855502
Cancer Chemother Pharmacol. 1994;34(6):522-6
pubmed: 7923564
Cancer Chemother Pharmacol. 1996;39(1-2):34-41
pubmed: 8995497
J Clin Oncol. 1995 Apr;13(4):894-901
pubmed: 7707116
Adv Drug Deliv Rev. 2013 Jan;65(1):36-48
pubmed: 23036225
J Med Chem. 2004 Dec 30;47(27):6716-29
pubmed: 15615521

Auteurs

Maja Bilip (M)

Great Ormond Street Institute of Child Health, UCL, London, UK.

Shreya Shah (S)

Great Ormond Street Institute of Child Health, UCL, London, UK.

Mayuran Mathiyalakan (M)

Great Ormond Street Institute of Child Health, UCL, London, UK.

Aristides D Tagalakis (AD)

Great Ormond Street Institute of Child Health, UCL, London, UK.

Stephen L Hart (SL)

Great Ormond Street Institute of Child Health, UCL, London, UK.

Ruhina Maeshima (R)

Great Ormond Street Institute of Child Health, UCL, London, UK.

Simon Eaton (S)

Great Ormond Street Institute of Child Health, UCL, London, UK.

Michael Orford (M)

Great Ormond Street Institute of Child Health, UCL, London, UK.

Elsa Irving (E)

Great Ormond Street Institute of Child Health, UCL, London, UK.

Alessia Di Florio (A)

Great Ormond Street Institute of Child Health, UCL, London, UK.

Claire Simons (C)

Great Ormond Street Institute of Child Health, UCL, London, UK.
School of Pharmacy and Pharmaceutical Sciences, College of Biomedical and Life Sciences, Cardiff University, Cardiff, UK.

Andrew W Stoker (AW)

Great Ormond Street Institute of Child Health, UCL, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH